Geode Capital Management’s Foghorn Therapeutics FHTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.8M | Buy |
807,674
+116,979
| +17% | +$550K | ﹤0.01% | 2873 |
|
|
2025
Q1 | $2.52M | Buy |
690,695
+7,832
| +1% | +$28.6K | ﹤0.01% | 2954 |
|
|
2024
Q4 | $3.22M | Buy |
682,863
+5,477
| +0.8% | +$25.9K | ﹤0.01% | 2952 |
|
|
2024
Q3 | $6.31M | Buy |
677,386
+146,276
| +28% | +$1.36M | ﹤0.01% | 2640 |
|
|
2024
Q2 | $3.05M | Buy |
531,110
+82,699
| +18% | +$476K | ﹤0.01% | 2975 |
|
|
2024
Q1 | $3.01M | Buy |
448,411
+61
| +0% | +$409 | ﹤0.01% | 2943 |
|
|
2023
Q4 | $2.89M | Buy |
448,350
+22,268
| +5% | +$144K | ﹤0.01% | 2971 |
|
|
2023
Q3 | $2.13M | Buy |
426,082
+19,534
| +5% | +$97.7K | ﹤0.01% | 3060 |
|
|
2023
Q2 | $2.86M | Buy |
406,548
+20,540
| +5% | +$145K | ﹤0.01% | 2988 |
|
|
2023
Q1 | $2.39M | Buy |
386,008
+15,759
| +4% | +$97.7K | ﹤0.01% | 2952 |
|
|
2022
Q4 | $2.36M | Buy |
370,249
+1,622
| +0.4% | +$10.3K | ﹤0.01% | 2974 |
|
|
2022
Q3 | $3.16M | Buy |
368,627
+12,120
| +3% | +$104K | ﹤0.01% | 2914 |
|
|
2022
Q2 | $4.85M | Buy |
356,507
+6,323
| +2% | +$86K | ﹤0.01% | 2714 |
|
|
2022
Q1 | $5.33M | Buy |
350,184
+2,789
| +0.8% | +$42.5K | ﹤0.01% | 2764 |
|
|
2021
Q4 | $7.94M | Buy |
347,395
+74,688
| +27% | +$1.71M | ﹤0.01% | 2606 |
|
|
2021
Q3 | $3.8M | Buy |
272,707
+34,963
| +15% | +$487K | ﹤0.01% | 3068 |
|
|
2021
Q2 | $2.54M | Buy |
237,744
+91,104
| +62% | +$972K | ﹤0.01% | 3190 |
|
|
2021
Q1 | $1.93M | Buy |
146,640
+14,128
| +11% | +$186K | ﹤0.01% | 3266 |
|
|
2020
Q4 | $2.69M | Buy |
+132,512
| New | +$2.69M | ﹤0.01% | 2918 |
|